DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) announced 2024 results and listed a number of accomplishments that will bring both product and grant revenue in the next ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

While plasma-derived fibrinogen is limited to topical and injectable hemostat products, the healthcare potential of recombinant fibrinogen is greater. By focussing on specific variants ...

The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.

It was the first drug produced through recombinant DNA technology and among the first genetically engineered products to be available to consumers. Following the success of Humulin, recombinant DNA ...

Figure 5: Distribution of market subsegments generated by the industry's leading recombinant protein brands within the 57% total market share in 2010. Four Amgen products will be the sector's ...

He also noted progress in the recombinant antigen program, with products expected to launch before the fiscal year-end. Management reiterated its guidance for 20% to 40% revenue growth in fiscal ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Purification of recombinant proteins by affinity and conventional chromatography procedures and quality control analysis of purified products. This includes investigator proteins of interest and ...

Allergen source Allergen Approximate sensitization rate (%) Hypoallergen approaches for immunotherapy Ref. Silver birch Bet v 1 60–98 Natural hypoallergens, allergen fragments, allergen trimer ...